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Abstract
Purpose
Analyze inter-fraction volumetric changes of lung tumors treated with stereotactic body radi-
ation therapy (SBRT) and determine if the volume changes during treatment can be pre-
dicted and thus considered in treatment planning.
Methods and Materials
Kilo-voltage cone-beam CT (kV-CBCT) images obtained immediately prior to each fraction
were used to monitor inter-fraction volumetric changes of 15 consecutive patients (18 lung
nodules) treated with lung SBRT at our institution (45–54 Gy in 3–5 fractions) in the year of
2011–2012. Spearman's (ρ) correlation and Spearman's partial correlation analysis was
performed with respect to patient/tumor and treatment characteristics. Multiple hypothesis
correction was performed using False Discovery Rate (FDR) and q-values were reported.
Results
All tumors studied experienced volume change during treatment. Tumor increased in vol-
ume by an average of 15% and regressed by an average of 11%. The overall volume
increase during treatment is contained within the planning target volume (PTV) for all
tumors. Larger tumors increased in volume more than smaller tumors during treatment
(q = 0.0029). The volume increase on CBCT was correlated to the treatment planning
gross target volume (GTV) as well as internal target volumes (ITV) (q = 0.0085 and q =
0.0039 respectively) and could be predicted for tumors with a GTV less than 22 mL. The vol-
ume increase was correlated to the integral dose (ID) in the ITV at every fraction (q =
0.0049). The peak inter-fraction volume occurred at an earlier fraction in younger patients
(q = 0.0122).
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Conclusions
We introduced a new analysis method to follow inter-fraction tumor volume changes and
determined that the observed changes during lung SBRT treatment are correlated to the ini-
tial tumor volume, integral dose (ID), and patient age. Furthermore, the volume increase
during treatment of tumors less than 22mL can be predicted during treatment planning. The
volume increase remained significantly less than the overall PTV expansion, and radiation
re-planning was therefore not required for the purpose of tumor control. The presence of the
studied correlations suggests that the observed volumetric changes may reflect some
underlying biologic process rather than random fluctuations.
Introduction
Stereotactic body radiation therapy (SBRT) or stereotactic ablative body radiotherapy
(SABR) has become a highly effective radiation regimen for both early stage primary non-
small cell lung cancer (NSCLC) and oligometastatic cancers to the lung. In this procedure,
highly conformal and precise radiation doses of 50–60 Gy are delivered in 3–5 fractions to a
malignant lung nodule, resulting in outstanding local control rate (>90% for early stage lung
nodules).[1–4]
Due to the very high dose delivered in each SBRT fraction, the procedure requires robust
patient immobilization, reproducible setup, accurate target delineation and sharp dose fall off
outside the treatment target to avoid increased toxicity associated with elevated dose deposition
in normal tissues. On-board kilo-voltage CBCT (kV-CBCT) can be used to improve the repro-
ducibility of treatment setup as well as monitor tumor volume changes during treatment and
evaluate the need for adaptive radiotherapy (ART) re-planning.[5–9]
Conventionally fractionated radiotherapy of lung nodules generally results in a time-depen-
dent decrease in tumor volume during treatment.[10, 11] It was initially assumed that negligi-
ble inter-fraction tumor volume changes would be observed during the short SBRT treatment
time; however, several recent studies have noted both decreases as well as increases in inter-
fraction volumes.[12–18]
There however remains significant ambiguity whether these changes are significant and/or
biologically meaningful. One source of uncertainty is that repeat imaging and volumetric anal-
ysis may result in small fluctuations in volume due to physiologic changes or imaging method-
ology, which may occur even in the absence of any treatment. Assuming volumetric
calculations are accurate and not due to imaging artifact, it is unclear whether the changes
occur in a random fashion or truly reflect the tumor’s response to radiation. This distinction is
important because, if the inter-fraction changes reflect a biologic tumor response, they can be
used as predictive marker, studied to better understand SBRT radiobiology, and applied to
adaptive treatment planning.
We hypothesize that if strong correlations can be found between the observed tumor vol-
ume changes and the radiation delivered or other patient parameters known at the onset of
treatment, it would provide support that the inter-fraction volumetric changes represent a bio-
logic response rather than random volume fluctuations. Furthermore, the correlations may be
used to understand the cause of these changes and better establish a prediction model for future
patients. To the best of our knowledge, there are no studies showing that inter-fraction volu-
metric changes during lung SBRT treatment are related to other variables known at onset of
treatment.
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Materials and Methods
Patients and treatment delivery protocol
An IRB-approved retrospective study was performed on 15 consecutive patients receiving lung
SBRT treatment with kV-CBCT imaging between November 1, 2011 and June 1, 2012. A total
of 20 lung nodules were treated in these patients; however, only 18 nodules could be unambigu-
ously delineated on kV-CBCT (Table 1).
During simulation, each patient had one free-breathing CT and one 4D-CT using the Sie-
mens SOMATOM CT scanner (Siemens Healthcare, Erlangen, Germany). Varian Respiratory
Position Management (RPM) system (Varian Medical Systems, Palo Alto, USA) was used to
trace breathing motion and generate 4D-CT scans. 4D-CT was co-registered with the free-
breathing CT and internal target volumes (ITV) where generated by combining the gross
tumor volume (GTV) generated during each phase of the breathing cycle. Target delineation
was performed by the attending physician using Eclipse treatment planning system (Varian
Medical Systems, Palo Alto, CA, USA) with a standard CT lung window. A 5–8 mmmargin
was used to expand ITV to planning target volume (PTV), with greater margins often given in
the superior-inferior direction per RTOG guidelines.
Treatment plans were generated using various planning techniques, including 7–10 field
non co-planer conformal technique and intensity modulated radiotherapy (IMRT). True-
BEAM™ system (Varian Medical Systems, Palo Alto, CA) was used to acquire pre-treatment
CBCTs for tumor position verification and treatment plan delivery. The CBCT images were
acquired using a preset thorax technique (125 kV voltage and 550 mAs). The images have an
Table 1. Patient parameters examined in the study.
Patient Neoplasm Age Tumor
Location
Volume of
Treated Lung
(mL)
ITV
Volume
(mL)
GTV
Volume
(mL)
Histology Prescribed Dose
per Fraction (Gy)
Number of
Fractions
1 I 85 Right Lung 1447 5 1.9 Unknown 10.0 5
2 II 80 Left Lung 863 72.8 47.5 Squamous cell 18.0 3
3 III 80 Right Lung 1375 19.2 11.5 Adenocarcinoma 10.0 5
4 IV 57 Right Lung 1878 22.8 16.9 Squamous 17.0 3
5 V 77 Left Lung 1938 82.9 46.6 Adenocarcinoma 10.0 5
6 VI 72 Left Lung 1333 10 6.3 Squamous cell 10.0 5
VII Right Lung 1814 2.6 0.7 Squamous cell 10.0 5
7 VIII 66 Right Lung 2057 5.5 3.2 Adenocarcinoma 9.0 5
8 IX 86 Left Lung 1071 77.2 57.1 Adenocarcinoma 10.0 5
9 X 82 Left Lung 1695 7.3 5.3 Squamous cell 10.0 5
XI Left Lung 1695 0.9 0.5 Unknown 10.0 5
XII Right Lung 1658 3.1 1.8 Unknown 10.0 5
10 XIII 63 Right Lung 2172 31 21.7 Squamous cell 10.0 5
11 XIV 70 Right Lung 1125 27 21.2 Adenocarcinoma 9.5 5
12 XV 64 Left Lung 1676 10.2 5.0 Atypical cells 10.0 5
13 XVI 66 Right Lung 1408 16.7 9.9 Adenocarcinoma 18.0 3
14 XVII 70 Right Lung 822 18.5 17.6 Adenocarcinoma 9.0 5
1Left Lung 602 16.5 10.6 Adenocarcinoma 9.0 5
15 XVIII 62 Right Lung 1612 4.4 3.6 Adenocarcinoma 18 3
1Left Lung 1127 3.5 2.1 Adenocarcinoma 10 5
1Not included in the study because of significant fibrosis/imaging artifacts.
doi:10.1371/journal.pone.0153245.t001
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in-plane resolution of 512 x 512 pixels, 2 mm slice thickness, and 17 cm longitudinal coverage.
CBCT images of each patient were co-registered with the planning CT.
Ethics Statement
This study was approved by the Cancer Institutional Review Board in the Office of Responsible
Research Practices. In addition, data pertaining to this study were de-identified prior to
analysis.
Contouring Protocol
To minimize inter-observer variability, tumors on all CBCTs were contoured using default
lung window settings by a single researcher, and then verified by an attending physician (Fig
1A). The target volumes including GTV, ITV, PTV were contoured and confirmed by the treat-
ing physician on the free breathing CT and 4DCT during simulation (Fig 1D).
The planning CT tumor volumes and the CBCT tumor volumes, as well as their corre-
sponding differential dose-volume histograms (dDVH) in 0.1 cGy increments were exported
into Matlab (MathWorks, Natick, MA) for further analysis. The integral dose (ID), in units of
cGycm3, was then calculated (Fig 1E and Fig 2). The average dose, in units of cGy, was deter-
mined by dividing the ID by the structure volume and cross-compared with the average dose
calculated by the treatment planning software.
Statistical analysis
The inter-fraction volume changes of each tumor were simplified to 7 parameters: first CBCT
volume (FCV), maximum volume (within the treatment course), minimum volume (within
the treatment course), days to maximum volume, fraction to maximum volume, days to
Fig 1. Summary of the analysis method.CBCTs were contoured by a single researcher and then verified by an attending physician (A), and the time
course of each tumor was simplified to 7 parameters (B). Treatment planning CT contours (D) were used to determine the integral dose (ID) of structures
listed in Table 2 (E). Each square in C represents a Spearman correlation analysis pair between inter-fraction volumes (B), EMR data, and treatment
parameters (E).
doi:10.1371/journal.pone.0153245.g001
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minimum volume, and fraction to minimum volume (Table 2). Correlation analysis between
each volume parameter (Fig 1B) and treatment planning data (Fig 1E) as well as tumor/patient
characteristics was then performed (Fig 1C). The correlation between numerical parameters
was determined by Spearman’s ρ that is sensitive to both linear and non-linear correlations.
Partial Spearman’s correlation analysis between two variables while controlling for a third vari-
able was also performed. The p-values were adjusted by linear step-up method of Benjamini
and Hochberg to control false discovery rate (FDR).[19] Q-values< 0.05 are considered signif-
icant, reported p-values represent statistical analysis without multiple hypothesis correction.
The volumes were compared both as absolute volume change in milliliters, denoted as
“(mL)”, and as values normalized to the FCV, denoted as “(%)”. Linear regression fitting was
performed on some of the data where noted and an r value as well as slope is reported. The
effect of tumor histology was studied with a two-tailed student's t-test. Data analysis was per-
formed by using SAS 9.4 (SAS, Inc; Cary, NC) and Matlab (MathWorks, Natick, MA).
Table 2. Parameters examined in the study.
CBCT Volume Parameters Patient/Tumor Parameters Treatment Parameters
Minimum Volume Age Prescribed Dose
Maximum Volume Lung Volume ITV Average Cumulative Dose
Days to Minimum Volume Histology non-PTV Average Cumulative Dose
Fractions to Minimum Volume GTV Volume ITV Average Dose per Fraction
Days to Maximum Volume ITV Volume non-PTV Average Dose per Fraction
Fraction to Maximum Volume ITV ID per Fraction
First CBCT Volume (FCV) non-PTV ID per Fraction
CBCT, cone-beam CT; PTV, planning target volume; ITV, internal target volume; ID, integral dose
doi:10.1371/journal.pone.0153245.t002
Fig 2. Integral dose calculations. Differential dose volume histogram (dDVH) of the ITV and non-PTV
contours was extracted from Eclipse treatment planning software with dose increments of 0.1cGy. Tumor
(ITV) volume in brown and healthy lung tissue (non-PTV) shown in green. The integral dose (ID) was
calculated by summing the product of the dose and volume at each dose. Average dose was calculated by
dividing the ID by structure volume.
doi:10.1371/journal.pone.0153245.g002
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Results
Patient characteristics and CBCT tumor contours
The patients included in the study had an average age of 73 (range: 57 to 86 years) and were
treated with a total of 45–54 Gy in 3 or 5 fractions (Table 1). Patients were treated every other
day with the exception of weekends (S1 Fig). The average FCV is 13.9 mL (range: 0.41 to 58.2
mL) (S1 Fig) and the average ipsilateral lung volume for these patients is 1535 mL (range: 822
to 2172 mL).
FCVs derived from CBCT were plotted with respect to the ITV and GTV generated by the
treating physician from planning CT, revealing a strong linear correlation (r = 0.98 for ITV and
r = 0.95 for GTV) (Fig 3). Since images from CBCT reflect those from average CTs (due to longer
time of CBCT image acquisition), FCV calculated from CBCT is more strongly correlated to ITV.
Numerically the FCV is approximately 62% of the ITV and 91% of GTV (Fig 3). The FCV is
slightly smaller than the GTV because CBCT contouring was performedmore conformally around
the tumor than for treatment planning to more accurately capture smaller volume changes.
To ensure similar treatment plans between physicians at our institute, the average ITV dose
was plotted with respect to the prescribed dose (Fig 4). The average ITV dose is in excellent
agreement with the physician prescribed dose with the ITV volume receiving approximately
20% more radiation than the prescription dose (since ITV is contained within PTV and all
treatment doses are prescribed to PTV).
Tumor volume change during treatment
An average maximum volume increase of 15.1% (0% to 48.8%) and an average maximum vol-
ume decrease of 10.6% (0% to 70.8%) relative to the FCV was observed (S1 Fig). Significant
tumor regression was noted in tumor III on CBCT, which was confirmed by repeat simulation
CT, and adaptive treatment re-planning was performed for fraction 3–5 (see S1 Appendix for
additional details). Because of this unusual change and the ensuing treatment re-planning, all
Fig 3. Contour volume of the treatment planning CT relative to first CBCT volume. FCV is approximately 62% of the ITV (r = 0.98) (A) and 91% of GTV
(r = 0.95) (B). Data point in red denotes the patient’s treatment was re-planned due to significant reduction in tumor volume.
doi:10.1371/journal.pone.0153245.g003
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statistical analyses are reported with the data from tumor III excluded; however, the inclusion
of tumor III does not appreciably alter the strength of the reported correlations.
Effect of tumor volume increase on dose coverage of tumors
Our analysis was not performed on the same imaging modality as the treatment planning and
it is therefore difficult to precisely determine the effect on dose coverage; however, if the vol-
ume increase is assumed to occur uniformly and not alter the shape of the tumor, it is possible
to approximate whether the tumor would extend beyond the PTV. Since the correlation
between treatment planning ITV and FCV was significant, the maximum inter-fraction vol-
ume increase on CBCT can be converted to an expected inter-fraction volume increase on
treatment planning CT using the 0.62 correlation factor calculated in Fig 3. The expected vol-
ume on treatment planning CT was plotted with respect to PTV (Fig 5). Using this method, the
increase in volume of all tumors in our study is significantly less than the PTV volume and the
volume increase is therefore expected to be contained within the PTV expansion (Fig 5).
Correlation Analysis
FCV/ITV/GTV vs. CBCT volume change. One of the most significant correlations is
between the FCV (mL) and the maximum volume in CBCT (mL) during treatment
(q = 0.0029); ITV and maximum volume (mL) (q = 0.0039); GTV and maximum volume (mL)
(q = 0.0085). It is important to note that the correlation analysis is a non-parametric test, mean-
ing the data has a trend but does not need to be linear to have a high correlation value. However,
examining the data suggest there is a linear correlation for smaller tumors. Performing linear
regression between the FCV and maximum volume during treatment (mL) revealed that the
maximum tumor volume is approximately 13% bigger than the first CBCT contour (Fig 6A),
9.4% bigger than treatment planning ITV, and 11.6% bigger than treatment planning GTV vol-
ume. Three large tumors (greater than 22mL GTV) were excluded from the linear regression due
to their large volumes; however, they are included in the correlation analysis above.
Fig 4. Physician prescribed dose vs average dose to ITV. The average ITV dose is calculated from the
dDVH and is in agreement with the prescribed dose.
doi:10.1371/journal.pone.0153245.g004
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The relationship between minimum volume of tumors during treatment and FCV, ITV,
GTV, or ITV ID per Fraction is nearly random (Table 3).
ITV ID per fraction vs. CBCT volume change. The ITV ID per fraction was directly cor-
related to the maximum volume (ml) (q = 0.0049). Neither the average dose delivered to the
ITV nor the average dose of the non-PTV (presumably healthy lung tissue) was correlated to
any inter-fraction tumor change parameter by a statistically significant margin (data not
shown). These findings suggest the volume increase observed on CBCT requires the deposition
of a large amount of energy at every fraction in the tumor.
Patient age vs. day/fraction maximum volume observed. Patient age at treatment onset
was positively correlated to the fraction (p = 0.0009 and q = 0.0122) when the maximum
tumor volume was observed (Table 3). The correlation between patient age and the day to max-
imum tumor volume did not reach statistical significance after multiple hypothesis correction
but was statistically significant prior to multiple hypothesis (q = 0.0972 and p = 0.0088). To
determine if these correlations are due to confounding variables, correlation analysis between
patient age and all other parameters was performed, resulting in a statistically significant corre-
lation only between non-PTV ID per fraction (healthy tissue irradiated) and patient age
(p = 0.0458). Also, visual inspection suggested the presence of covariance between lung volume
and patient age that did not reach a statistically significant threshold (p = 0.2010). To account
for potential confounding covariance, a correlation analysis between patient age and day to
maximum volume as well as fraction of maximum volume was repeated while controlling for
both non-PTV ID per fraction and lung volume. Controlling for these variables resulted in a
stronger correlation between age and the day of maximum volume (p = 0.0063), as well as a
stronger correlation between age and treatment fraction of maximum volume (p = 0.0006).
This suggests patient age is an independent predictor of the day when the maximum volume
occurs, with respect to variables included in our study
Fig 5. Expected volume increase on CT from original ITV volume with respect to PTV.Original ITV
volume in orange and the expected volume increase on CT is in blue. The expected increase on CT was
calculated using the 0.62 correlation factor from Fig 3. The diagonal line represents the maximum volume that
can reside in the PTV.
doi:10.1371/journal.pone.0153245.g005
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Tumor histology vs. CBCT tumor volume parameters. A two-tailed t-test of the 7 volu-
metric parameter averages with respect to tumor histology was performed and did not reveal
any statistically significant differences. Parameters having the strongest difference between
squamous cell and adenocarcinoma histology are displayed in S1 Table.
Discussion
Although several groups have previously demonstrated the presence of volumetric fluctuations
during SBRT treatment of the lung, it is not clear if the observed inter-fraction changes are due
Fig 6. Linear regression between the FCV andmaximum inter-fraction volume. Points in green were excluded from the linear regression due to their
large volumes relative to the other points, but are included in the correlation analysis. Data point in red was excluded because the patient’s treatment was re-
planned.
doi:10.1371/journal.pone.0153245.g006
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to random fluctuations in volume, errors in tumor measurements, such as imaging artifacts, or
represents a true biologic response, such as inflammation or tumor growth [12–18]
Progress in this area has been hampered by the absence of a simple and robust analysis
method that accurately captures trends in both volume increase as well as decrease, especially
when they occur during the same treatment course.
A New Analysis Method
In the present study we have employed a new methodology to quantify and classify volume
changes during SBRT. One method that has been previously described is normalizing the volu-
metric changes by the initial volume and averaging the normalized volumes at each treatment
fraction.[14, 16, 17] This method has two important limitations: only normalized volumes (%)
can be analyzed and it assumes that volume changes occur at approximately the same time in
different tumors (Fig 7). Using normalized volumes tends to bias the analysis toward smaller
tumors since minor changes in volume correspond to large normalized volume changes. Sec-
ondly, the assumption that inter-fraction changes occur at similar timescales between different
tumors is improbable and may therefore result in loss of statistically significant correlations
(Fig 7). Our methodology ameliorates the above limitations. Simplifying the inter-fraction vol-
ume traces of each tumor to 7 parameters (Table 1 CBCT parameters) allows us to examine
both normalized and non-normalized volumes. Furthermore, this allows us to perform correla-
tion analysis of both the changes in tumor volume as well as the time when these changes
occur, without assuming volume changes occur at the same time between different tumors
Larger tumors increase in volume to a greater extent than smaller tumors
To our knowledge, this is the first report of inter-fraction volumetric changes during SBRT
lung treatment being correlated to variables known at treatment onset. The presence of correla-
tion between initial tumor volume and the maximum tumor volume as well as the lack of cor-
relation between the initial tumor volume and minimum volume during treatment strongly
suggests that the correlation between the initial tumor volume and maximum tumor volume is
not an imaging artifact or random fluctuations in tumor volume. If the correlation was an
imaging artifact or random fluctuations in tumor volume, we would expect either that the ini-
tial tumor volume would be correlated to both the maximum volume and the minimum vol-
ume since both a numeric increase in volume as well as decrease would be equally likely or we
would expect no correlation at all.
The maximum inter-fraction tumor volume can be predicted from the FCV and an average
maximum volume increase of approximately 13%, relative to the FCV, can be expected during
SBRT treatment of the lung. Furthermore, the volume increase during treatment corresponds
Table 3. Inter-fraction variables with significant correlation coefficients. Spearman correlation coeffi-
cient listed with q-values in parenthesis.
Maximum Volume (mL) Minimum Volume (mL)
First cone-beam CT (FCV) 0.8112 (q = 0.0029) -0.1092 (q = 0.9846)
ITV 0.7966 (q = 0.0039) -0.1219 (q = 0.9754)
GTV 0.7647 (q = 0.0085) -0.0914 (q = 0.9846)
ITV ID per Fraction 0.7868(q = 0.0049) -0.0660 (q = 0.9846)
Day of Maximum Volume Fraction of Maximum Volume
Patient Age 0.6133(q = 0.0972) 0.7274(q = 0.0122)
ITV, internal target volume; ID, integral dose
doi:10.1371/journal.pone.0153245.t003
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to an increase of 9.4% relative to ITV and 11.6% relative to GTV. However, it’s important to
note that the volume increase could only be predicted for tumors with a GTV less than 22 mL
in our study.
Our observed correlation may be due to characteristics of the tumor (ie size, histology,
tumor biology) or radiation delivery parameters (ie dose, fractionation, ID). It is unclear
whether the inability to predict the volume increase in larger tumors is due to biologic causes
or simply because not enough large tumors were included in the study.
The maximum volume increase was not correlated to the treatment dose but it was corre-
lated to the integral dose (ID) delivered to the ITV at every fraction. Since slightly different
fractionation protocol was used in our study, we employed ID as one parameter to compare all
tumors in our study. ID represents the energy deposited in the tumor and is a function of
tumor volume, average dose, and some contribution from dose homogeneity. Since the ID gen-
erally scales with tumor volume, assuming uniform dose coverage, this finding does not distin-
guish whether the volume increase is independently linked to initial tumor volume or whether
it is linked to increased radiation delivery. The similar correlation between maximum tumor
volume and FCV as well as maximum tumor volume and ID delivered to the ITV, in addition
to a lack of other correlations with these variables; suggest that initial tumor volume may inde-
pendently predict volume increase during treatment, even in the presence of varying SBRT
treatment protocols.
Using a different approach, Gunter et al. observed maximum inter-fraction volume of 115%
and 110% in lung tumors treated with SBRT in 3 and 5 fractions respectively.[14] The cumula-
tive increases and decrease of all tumors in the study were statistically significant; however, nei-
ther the maximum nor minimum volume changes could be predicted for individual tumors. It
is important to note that the above study examined only the normalized data relative to FCV
Fig 7. Loss of statistically significant correlations occurs when tumor volumes are averaged. If three
tumors have the same volume increase during treatment yet occur at different times (A), simple averaging of
the 3 volume time-courses will result in a curve with large standard error that significantly underestimates the
volume increase (B).
doi:10.1371/journal.pone.0153245.g007
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whereas the correlation between maximum volumes and FCVs was only apparent in our study
when the volume changes were analyzed without normalization.
Inter-fraction volume increase does not exceed the PTV
The observed volume increase is relatively small and tumors have significant room to expand
before reaching PTV volume. Therefore the volume increase is unlikely to affect PTV coverage.
One patient’s volume decreased significantly and his treatment plan was modified after the sec-
ond fraction. Our experience showed that this is rare and tumor volume changes in most situa-
tions do not warrant adaptive re-planning.
Patient age correlated to the fraction when maximum inter-fraction
volume is observed
Patient age is correlated to the treatment fraction when the peak inter-fraction volume is
observed. Our finding that repeating the correlation analysis between patient age while control-
ling for potential confounding variables (lung volume and non-PTV ID per fraction) results in
stronger correlations was intriguing and requires further study. Specifically, it is not clear
whether patient age is driving inter-fraction volumetric changes or if age indirectly affects
treatment parameters that were not measured in this study.
Many biologic changes associated with the aging process may lead to this observation. For
example, it has previously been hypothesized that inter-fraction volume increases during SBRT
may be due to inflammation or edema.[14, 15] In the context of edema, the delayed onset of
the volume increase in older age in our cohort may be explained by age-dependent dysregula-
tion of the immune system.[20]
Conclusion
Tumor volume fluctuations during SBRT of the lung were monitored by analyzing kV-CBCT
images obtained before each treatment fraction, revealing both increases and decreases in
tumor volume during treatment. Using our novel analysis method, we showed that these vol-
ume fluctuations were correlated to GTV, ITV, ITV ID per fraction, and patient age. In addi-
tion, volume increase for tumors less than 22mL could be predicted from treatment planning
GTV or ITV. These findings suggest that inter-fraction volume fluctuations during SBRT treat-
ment is not a random fluctuation or an imaging artifact but may reflects a biologic response
and its clinical use should be further explored.
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